Lipocine director granted rights to buy 1,764 shares

Higuchi John W. reported acquisition or exercise transactions in this Form 4 filing.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Higuchi John W. reported acquisition or exercise transactions in this Form 4 filing.

Lipocine Inc. director John W. Higuchi received a grant of derivative securities giving him the right to buy 1,764 shares of common stock at $2.19 per share. These rights vest 100% one year from the grant date and expire on June 3, 2036. Following this award, Higuchi holds rights to purchase a total of 13,290 shares of common stock.

Insider Trade Summary

Grant/Award: 1,764 shares

Grant/Award 1 txn

Insider Higuchi John W.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock (Right to Buy)	1,764	$2.19	$4K

Holdings After Transaction: Common Stock (Right to Buy) — 13,290 contracts (Direct)

Footnotes (1)

F1. 100% vesting upon one year from date of grant.

Key Figures

Granted derivative shares: 1,764 shares Exercise price: $2.19 per share Total derivative holdings after grant: 13,290 shares +3 more

6 metrics

Granted derivative shares 1,764 shares Right to buy common stock granted to director

Exercise price $2.19 per share Conversion or exercise price for granted rights

Total derivative holdings after grant 13,290 shares Rights to buy Lipocine common stock

Grant date June 3, 2026 Date of derivative grant to director

Vesting schedule 100% after one year Footnote: full vesting one year from grant date

Expiration date June 3, 2036 Derivative securities expiration

Key Terms

Common Stock (Right to Buy), Grant, award, or other acquisition, vesting, exercise price

4 terms

Common Stock (Right to Buy) financial

"security_title: Common Stock (Right to Buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

vesting financial

"100% vesting upon one year from date of grant."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exercise price financial

"conversion_or_exercise_price: 2.1900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Lipocine (LPCN) director John W. Higuchi report?

John W. Higuchi reported receiving a grant of derivative securities for 1,764 shares of Lipocine common stock. The grant gives him the right to buy these shares at $2.19 per share as part of his compensation package.

At what price can John W. Higuchi buy Lipocine (LPCN) shares from this grant?

The grant allows John W. Higuchi to buy 1,764 Lipocine common shares at an exercise price of $2.19 per share. This price is fixed in the award and applies when the rights are exercised after vesting.

When do John W. Higuchi’s new Lipocine (LPCN) equity awards vest and expire?

The 1,764-share right-to-buy award vests 100% one year from the June 3, 2026 grant date. The derivative securities expire on June 3, 2036, giving a long exercise window after vesting is completed.

How many Lipocine (LPCN) shares can John W. Higuchi buy after this Form 4 transaction?

After this grant, John W. Higuchi holds rights to purchase 13,290 shares of Lipocine common stock in total. This figure reflects his derivative holdings following the newly awarded 1,764-share right-to-buy grant.

Is John W. Higuchi’s Lipocine (LPCN) Form 4 a market purchase or a compensation grant?

The Form 4 reports a compensation-related grant coded “A” as a grant, award, or other acquisition. It is not an open-market stock purchase but an option-style right to buy shares at $2.19 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/04/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Higuchi John W.

(Last)

(First)

(Middle)

C/O 675 ARAPEEN DR

SUITE 202

(Street)

SALT LAKE CITY

UTAH

84108

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lipocine Inc. [ LPCN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock (Right to Buy)	$2.19	06/03/2026		A		1,764		06/03/2027⁽¹⁾	06/03/2036	Common Stock	1,764	$2.19	13,290	D

Explanation of Responses:

1. 100% vesting upon one year from date of grant.

	/s/ John W. Higuchi	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR